Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors.

Trial Profile

Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs E 7016 (Primary) ; Temozolomide (Primary)
  • Indications Glioma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top